Drugs / Ir-CPI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04653766 | Sep 2019 → Jul 2020 | — | Bioxodes S.A. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05970224 | Nov 2023 → Mar 2026 overdue | intracerebral hemorrhage | Bioxodes S.A. | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-29 | Bioxodes S.A. | Results Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI bioxodes.com ↗
Bioxodes, a clinical stage biotechnology company announces today the completion of the active phase of its First-in-Human (FIH) study with Ir-CPI dedicated to the prevention of thrombosis. |
| 2019-10-15 | Bioxodes S.A. | Regulatory Bioxodes obtains authorization to launch Phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers bioxodes.com ↗ |
All press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-04-29 | Bioxodes S.A. | Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI bioxodes.com ↗ |
| 2019-10-15 | Bioxodes S.A. | Bioxodes obtains authorization to launch Phase I trial of its antithrombotic drug, Ir-CPI, in healthy male volunteers bioxodes.com ↗ |
| 2015-06-01 | Bioxodes S.A. | Bioxodes raises EUR 7.9 million to bring Ir-CPI to the clinic bioxodes.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ir-CPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05970224 ↗ |
| Known as | Ixodes Ricinus-Contact Phase Inhibitor | “A Study to Evaluate the Safety, Tolerability and the Effects of Ixodes Ricinus-Contact Phase Inhibitor (Ir-CPI) in Adult Patients With Spontaneous Intracerebral Haemorrhage” NCT05970224 ↗ |
| Action | Inhibit | “a novel dual inhibitor of FXIIa and FXIa” NCT04653766 ↗ |
| Route | Intravenous | “following IV administration of single ascending doses” NCT04653766 ↗ |